FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.

Autor: Samms RJ; Eli Lilly and Company, Indianapolis, Indiana., Cheng CC; Eli Lilly and Company, Indianapolis, Indiana., Fourcaudot M; Diabetes Division, University of Texas Health San Antonio, San Antonio, Texas., Heikkinen S; Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland., Khattab A; Diabetes Division, University of Texas Health San Antonio, San Antonio, Texas., Adams J; Diabetes Division, University of Texas Health San Antonio, San Antonio, Texas., Cersosimo E; Diabetes Division, University of Texas Health San Antonio, San Antonio, Texas., Triplitt C; Diabetes Division, University of Texas Health San Antonio, San Antonio, Texas., Puckett C; Diabetes Division, University of Texas Health San Antonio, San Antonio, Texas., Tsintzas K; School of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham, United Kingdom., Adams AC; Eli Lilly and Company, Indianapolis, Indiana., Abdul-Ghani MA; Diabetes Division, University of Texas Health San Antonio, San Antonio, Texas., DeFronzo RA; Eli Lilly and Company, Indianapolis, Indiana., Norton L; Diabetes Division, University of Texas Health San Antonio, San Antonio, Texas.

Publikováno v: American journal of physiology. Endocrinology and metabolism [Am J Physiol Endocrinol Metab] 2022 Aug 01; Vol. 323 (2), pp. E123-E132. Date of Electronic Publication: 2022 Jun 20.

The Insulin-Sensitizer Pioglitazone Remodels Adipose Tissue Phospholipids in Humans.

Autor: Palavicini JP; Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.; Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States., Chavez-Velazquez A; Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States., Fourcaudot M; Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States., Tripathy D; Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States., Pan M; Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.; Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States., Norton L; Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States., DeFronzo RA; Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States., Shannon CE; Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.

Publikováno v: Frontiers in physiology [Front Physiol] 2021 Dec 02; Vol. 12, pp. 784391. Date of Electronic Publication: 2021 Dec 02 (Print Publication: 2021).

Further evidence supporting a potential role for ADH1B in obesity.

Autor: Morales LD; South Texas Diabetes and Obesity Institute Department of Human Genetics, School of Medicine, University of Texas Rio Grande Valley, Edinburg/Harlingen/Brownsville, TX, USA. liza.morales@utrgv.edu., Cromack DT; South Texas Veterans Health Care System, San Antonio, TX, USA., Tripathy D; South Texas Veterans Health Care System, San Antonio, TX, USA.; Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA., Fourcaudot M; Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA., Kumar S; South Texas Diabetes and Obesity Institute Department of Human Genetics, School of Medicine, University of Texas Rio Grande Valley, Edinburg/Harlingen/Brownsville, TX, USA., Curran JE; South Texas Diabetes and Obesity Institute Department of Human Genetics, School of Medicine, University of Texas Rio Grande Valley, Edinburg/Harlingen/Brownsville, TX, USA., Carless M; Department of Population Health, Texas Biomedical Research Institute, San Antonio, TX, USA., Göring HHH; South Texas Diabetes and Obesity Institute Department of Human Genetics, School of Medicine, University of Texas Rio Grande Valley, Edinburg/Harlingen/Brownsville, TX, USA., Hu SL; University of Texas Health Houston, School of Public Health, Brownsville, TX, USA., Lopez-Alvarenga JC; South Texas Diabetes and Obesity Institute Department of Human Genetics, School of Medicine, University of Texas Rio Grande Valley, Edinburg/Harlingen/Brownsville, TX, USA., Garske KM; Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Pajukanta P; Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Small KS; King's College London, London, UK., Glastonbury CA; King's College London, London, UK., Das SK; Internal Medicine-Endocrinology and Metabolism, Wake Forest School of Medicine, Winston-Salem, NC, USA., Langefeld C; Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC, USA., Hanson RL; Phoenix Epidemiology and Clinical Research Branch, NIDDK, Phoenix, AZ, USA., Hsueh WC; Phoenix Epidemiology and Clinical Research Branch, NIDDK, Phoenix, AZ, USA., Norton L; Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA., Arya R; South Texas Diabetes and Obesity Institute Department of Human Genetics, School of Medicine, University of Texas Rio Grande Valley, Edinburg/Harlingen/Brownsville, TX, USA., Mummidi S; South Texas Diabetes and Obesity Institute Department of Human Genetics, School of Medicine, University of Texas Rio Grande Valley, Edinburg/Harlingen/Brownsville, TX, USA., Blangero J; South Texas Diabetes and Obesity Institute Department of Human Genetics, School of Medicine, University of Texas Rio Grande Valley, Edinburg/Harlingen/Brownsville, TX, USA., DeFronzo RA; South Texas Veterans Health Care System, San Antonio, TX, USA.; Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA., Duggirala R; South Texas Diabetes and Obesity Institute Department of Human Genetics, School of Medicine, University of Texas Rio Grande Valley, Edinburg/Harlingen/Brownsville, TX, USA., Jenkinson CP; South Texas Diabetes and Obesity Institute Department of Human Genetics, School of Medicine, University of Texas Rio Grande Valley, Edinburg/Harlingen/Brownsville, TX, USA. christopher.jenkinson@utrgv.edu.

Publikováno v: Scientific reports [Sci Rep] 2021 Jan 21; Vol. 11 (1), pp. 1932. Date of Electronic Publication: 2021 Jan 21.

Suppression of the postprandial hyperglycemia in patients with type 2 diabetes by a raw medicinal herb powder is weakened when consumed in ordinary hard gelatin capsules: A randomized crossover clinical trial.

Autor: Moreira, Fernanda Duarte^1,2,3 (AUTHOR), Reis, Caio Eduardo Gonçalves⁴ (AUTHOR), Gallassi, Andrea Donatti³ (AUTHOR), Moreira, Daniel Carneiro⁵ (AUTHOR), Welker, Alexis Fonseca³ (AUTHOR) welker.af@gmail.com

Publikováno v: PLoS ONE. 10/9/2024, Vol. 19 Issue 10, p1-58. 58p.

Interrelationships among metabolic syndrome, bone-derived cytokines, and the most common metabolic syndrome-related diseases negatively affecting bone quality.

Autor: Martiniakova, Monika¹ (AUTHOR), Mondockova, Vladimira² (AUTHOR), Kovacova, Veronika¹ (AUTHOR), Babikova, Martina² (AUTHOR), Zemanova, Nina¹ (AUTHOR), Biro, Roman¹ (AUTHOR), Penzes, Noemi² (AUTHOR), Omelka, Radoslav² (AUTHOR) romelka@ukf.sk

Publikováno v: Diabetology & Metabolic Syndrome. 9/6/2024, Vol. 16 Issue 1, p1-26. 26p.